About Short transient receptor potential channel 3
Short transient receptor potential channel 3 (TRPC3) is a protein
from Homo sapiens identified by UniProt accession
Q13507, 921 residues long.
MolForge cross-references it against 0 known binders and
224 disease associations.
Target properties
| Protein name | Short transient receptor potential channel 3 |
|---|
| UniProt accession | Q13507 |
|---|
| Gene | TRPC3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 921 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (224)
Diseases linked to this target (Open Targets).
- Spinocerebellar ataxia type 41 · score 0.62
- neurodegenerative disease · score 0.33
- breast adenocarcinoma · score 0.27
- glioblastoma multiforme · score 0.24
- self reported educational attainment · score 0.22
- lung adenocarcinoma · score 0.21
- cutaneous melanoma · score 0.21
- protein measurement · score 0.21
- psoriasis · score 0.17
- head and neck squamous cell carcinoma · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q13507-F1 | alphafold | PREDICTED | 78.30 | — |
Amino-acid sequence (921 residues)
MSTKVRKCKE QARVTFPAPE EEEDEGEDEG AEPQRRRRGW RGVNGGLEPR SAPSQREPHG YCPPPFSHGP DLSMEGSPSL RRMTVMREKG RRQAVRGPAF MFNDRGTSLT AEEERFLDAA EYGNIPVVRK MLEESKTLNV NCVDYMGQNA LQLAVGNEHL EVTELLLKKE NLARIGDALL LAISKGYVRI VEAILNHPGF AASKRLTLSP CEQELQDDDF YAYDEDGTRF SPDITPIILA AHCQKYEVVH MLLMKGARIE RPHDYFCKCG DCMEKQRHDS FSHSRSRINA YKGLASPAYL SLSSEDPVLT ALELSNELAK LANIEKEFKN DYRKLSMQCK DFVVGVLDLC RDSEEVEAIL NGDLESAEPL EVHRHKASLS RVKLAIKYEV KKFVAHPNCQ QQLLTIWYEN LSGLREQTIA IKCLVVLVVA LGLPFLAIGY WIAPCSRLGK ILRSPFMKFV AHAASFIIFL GLLVFNASDR FEGITTLPNI TVTDYPKQIF RVKTTQFTWT EMLIMVWVLG MMWSECKELW LEGPREYILQ LWNVLDFGML SIFIAAFTAR FLAFLQATKA QQYVDSYVQE SDLSEVTLPP EIQYFTYARD KWLPSDPQII SEGLYAIAVV LSFSRIAYIL PANESFGPLQ ISLGRTVKDI FKFMVLFIMV FFAFMIGMFI LYSYYLGAKV NAAFTTVEES FKTLFWSIFG LSEVTSVVLK YDHKFIENIG YVLYGIYNVT MVVVLLNMLI AMINSSYQEI EDDSDVEWKF ARSKLWLSYF DDGKTLPPPF SLVPSPKSFV YFIMRIVNFP KCRRRRLQKD IEMGMGNSKS RLNLFTQSNS RVFESHSFNS ILNQPTRYQQ IMKRLIKRYV LKAQVDKEND EVNEGELKEI KQDISSLRYE LLEDKSQATE ELAILIHKLS EKLNPSMLRC E
Explore Short transient receptor potential channel 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets